Mankind Pharma reported strong fourth-quarter operating performance driven by healthy domestic demand, chronic therapy growth and improved margins, while international business growth remained muted amid geopolitical challenges.
Mankind Pharma reported strong fourth-quarter operating performance driven by healthy domestic demand, chronic therapy growth and improved margins, while international business growth remained muted amid geopolitical challenges.